Combined Detection of High-Mobility Group Box 1 Protein Macrophage Migration Inhibitory Factor (MIF) and CXC Chemokine Subfamily 16 for the Diagnosis of High-Risk Human Papillomavirus Infection
CAI Rongrong, SHI Pingping, GU Chunyan
Nantong Haimen People's Hospital, Jiangsu Nantong 226100, China
Abstract：Objective: To investigate the expression levels and diagnostic value of high-mobility group box 1 protein (HMGB1), macrophage migration inhibitory factor (MIF), and CXC chemokine subfamily 16 (CXCL16) in patients with high-risk human papillomavirus (HPV) infection. Methods: A total of 150 patients with HPV infection admitted to our hospital from October 2020 to October 2023 were enrolled in the study group and divided into high-risk HPV infection group (n=40) and low-risk HPV infection group (n=110) according to the results of nucleic acid detection. Another 100 healthy women who underwent transvaginal colposcopy in our hospital during the same period were selected as the control group. The HPV-DNA genotyping kit was used to detect HPV in the study group patients; enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of HMGB1 and CXCL16 in the study group and control group; and immunohistochemistry was used to detect the staining intensity of MIF. The differences in HMGB1, MIF, and CXCL16 between the control group and the study group were compared; the differences in HMGB1, MIF, and CXCL16 between the low-risk HPV infection group and the high-risk HPV infection group were compared; receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of HMGB1, MIF, and CXCL16 combined detection for high-risk HPV infection; Spearman correlation analysis was used to analyze the correlation between HMGB1, MIF, and CXCL16 and different HPV infection genotypes. Results: Compared with the control group, the levels of serum HMGB1 and CXCL16, and the score of MIF positive cell proportion in the study group were significantly higher (all P<0.05); compared with the low-risk HPV infection group, the levels of serum HMGB1 and CXCL16, and the score of MIF positive cell proportion in the high-risk HPV infection group were significantly higher (all P<0.05); ROC curve analysis showed that the AUC of HMGB1, MIF, and CXCL16 for the diagnosis of high-risk HPV infection alone and in combination were 0.748, 0.684, 0.791, and 0.934, respectively. The diagnostic value of combined detection was significantly higher than that of single detection (Z=2.577, 3.152, 2.096, all P<0.05); Spearman correlation analysis showed that HMGB1, MIF, and CXCL16 were significantly positively correlated with different HPV infection genotypes (r=0.615, 0.633, 0.649, all P<0.05). Conclusion: The levels of serum HMGB1 and CXCL16, and the score of MIF positive cell proportion in patients with high-risk HPV infection were significantly higher than those in the low-risk and control groups. The combined detection of HMGB1, MIF, and CXCL16 in clinical examination can improve the clinical diagnosis rate of high-risk HPV infection and provide a new detection method and treatment basis for clinical practice.
蔡蓉蓉, 施平平, 顾春燕. 高迁移率族蛋白B1 巨噬细胞转移抑制因子联合CXC亚家族趋化因子16对高危型HPV感染患者诊断价值[J]. 河北医学, 2024, 30(7): 1160-1165.
CAI Rongrong, SHI Pingping, GU Chunyan. Combined Detection of High-Mobility Group Box 1 Protein Macrophage Migration Inhibitory Factor (MIF) and CXC Chemokine Subfamily 16 for the Diagnosis of High-Risk Human Papillomavirus Infection. HeBei Med, 2024, 30(7): 1160-1165.
[1] 廖旭慧,周璐青,卢洪胜,等.HPV感染宫颈病变组织中E2F1和P-Akt及miR-424与COX-2 mRNA水平[J].中华医院感染学杂志,2023,33(19):2984-2988. [2] 冯庆丰.重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察[J].中外女性健康研究,2022(13):57-58. [3] Jing F,Wang J,Zhou L,et al.Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor[J].Aging(Albany NY),2021,13(13):17789-17817. [4] Yuan Y,Cai X,Shen F,et al.HPV post-infection microenvironment and cervical cancer[J].Cancer Lett,2021,497:243-254. [5] Wang W,Gao X,Zhu Y,et al.Diagnostic significance of a color Doppler ultrasound combined with serum CXCL16 and E-cad in cervical cancer[J].Transl Cancer Res,2021,10(3):1492-1499. [6] Ntanasis-Stathopoulos I,Kyriazoglou A,Liontos M,et al.Current trends in the management and prevention of human papillomavirus(HPV)infection[J].BUON,2020,25(3):1281-1285. [7] 李明珠,魏丽惠.HPV的致瘤机制及以此预防HPV感染的研究进展[J].中华妇产科杂志,2022,57(2):152-155. [8] Ma T,Guo J,Han J,et al.Circ_0001589/miR-1248/HMGB1 axis enhances EMT-mediated metastasis and cisplatin resistance in cervical cancer[J].Mol Carcinog,2023,62(11):1645-1658. [9] 陈慧,陈光辉,王万党,等.宫颈癌患者HMGA1、HMGB1表达水平与高危型HPV感染的关系及临床意义[J].分子诊断与治疗杂志,2021,13(8):1353-1356,1360.
2024, Vol. 30 
冀公网安备13080202000677号